Polycythemia vera

Common Name(s)

Polycythemia vera

Polycythemia vera (PV) is a condition characterized by an increased number of red blood cells in the bloodstream. Affected people may also have excess white blood cells and platelets. These extra cells cause the blood to be thicker than normal, increasing the risk for blood clots that can block blood flow in arteries and veins. People with PV have an increased risk of deep vein thrombosis which can cause a pulmonary embolism, heart attack, and stroke. Most cases of PV are not inherited and are acquired during a person's lifetime. In rare cases, the risk for PV runs in families and may be inherited in an autosomal dominant manner. The condition has been associated with mutations in the JAK2 and TET2 genes.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Polycythemia vera" returned 421 free, full-text research articles on human participants. First 3 results:

Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera: A Case Report.
 

Author(s): Alessandra Iurlo, Lorenzo Dagna, Daniele Cattaneo, Nicola Orofino, Paola Bianchi, Giulio Cavalli, Claudio Doglioni, Umberto Gianelli, Agostino Cortelezzi

Journal: Medicine (Baltimore). 2016 May;95(20):e3697.

 

Erdheim-Chester disease is a rare form of non-Langerhans cell histiocytosis characterized by the migration and infiltration of lipid-laden CD68, CD1a and S100 histiocytes to various target organs, which leads to the disruption of physiological tissue architecture and reactive fibrosis, ...

Last Updated: 20 May 2016

Go To URL
Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience.
 

Author(s): Sadia Sultan, Syed Mohammed Irfan, Sadia Rashid Khan

Journal: Asian Pac. J. Cancer Prev.. 2016 ;17(3):1053-5.

 

Polycythemia rubra vera (PV), being a primary polycythemia, is caused by neoplastic proliferation of erythroid, megakaryocytic and granulocytic lineages which result in panmyelosis. PV patients have a somatic acquired mutation in the Janus kinase (JAK2) pathway, rendering cell proliferation ...

Last Updated: 4 Apr 2016

Go To URL
Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
 

Author(s): Shixiang Zhao, Xiang Zhang, Yang Xu, Yufeng Feng, Wenhong Sheng, Jiannong Cen, Depei Wu, Yue Han

Journal:

 

Most patients with polycythemia vera (PV) and half of essential thrombocythemia (ET) possess an activating JAK2V617F mutation. The objective of this study was to better define the effect of JAK2V617F mutant allele burden on clinical phenotypes in Chinese patients, especially thrombosis. ...

Last Updated: 26 Feb 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Polycythemia vera" returned 31 free, full-text review articles on human participants. First 3 results:

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
 

Author(s): Jeffrey C Bryan, Srdan Verstovsek

Journal: Cancer Chemother. Pharmacol.. 2016 06;77(6):1125-42.

 

Myelofibrosis (MF) and polycythemia vera (PV) are BCR-ABL1-negative myeloproliferative neoplasms associated with somatic hematopoietic stem cell mutations leading to over activation of JAK-STAT signaling. MF and PV are pathogenically related and share specific clinical features such ...

Last Updated: 27 May 2016

Go To URL
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
 

Author(s): T Barbui, J Thiele, A M Vannucchi, A Tefferi

Journal:

 

The 2001/2008 World Health Organization (WHO)-based diagnostic criteria for polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) were recently revised to accomodate new information on disease-specific mutations and underscore distinguishing morphologic ...

Last Updated: 2 Feb 2016

Go To URL
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
 

Author(s): S Cerquozzi, A Tefferi

Journal:

 

Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three BCR-ABL1-negative myeloproliferative neoplasms and are characterized by relatively long median survivals (approximately 14 and 20 years, respectively). Potentially fatal disease complications in ...

Last Updated: 14 Nov 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features
 

Status: Not yet recruiting

Condition Summary: Polycythemia Vera

 

Last Updated: 21 Jun 2016

Go to URL

Last Updated: 2 Sep 2016

Go to URL